Robert Davis Compass
Dr. Sarah Chen, MD • Dana-Farber Cancer Institute
Phase 2 Study of Targeted Combination Therapy in EGFR-Mutated Advanced NSCLC
Inviting candidate for screening protocol participation.
Candidate #PT-4109. Your name and contact coordinates remain completely hidden until you affirmatively click "I'm Interested in Connecting".
AI Clinical Synthesis & Staging
View Original Clinical Notes Entered
58-year-old male with recurrent Stage IV NSCLC. Molecular profiling positive for EGFR L858R. Prior lines include carboplatin/pemetrexed and osimertinib. Patient is active, ECOG 0, seeking trial options.
Key Eligibility Checklist
Top Matched Clinical Trials
Ranked by AI matching score against protocol inclusion and exclusion criteria.
Phase 2 Study of Targeted Combination Therapy in EGFR-Mutated Advanced NSCLC
A prospective open-label Phase 2 study evaluating third-generation EGFR TKI in combination with bispecific antibody therapy in patients with advanced non-small cell lung cancer harboring sensitizing EGFR mutations following frontline disease progression.
- ✓ Matches EGFR Exon 19 deletion
- ✓ Eligible with prior 1st-generation TKI progression
- ✓ Permits treated asymptomatic CNS metastases
- ✓ Local trial center within 5 miles
Study of Novel Brain-Penetrant TKI in Patients with EGFR-Mutant NSCLC and CNS Metastases
Evaluating efficacy and safety of a next-generation brain-penetrant kinase inhibitor in metastatic NSCLC patients with documented active or treated intracranial lesions.
- ✓ Matches EGFR mutation and Stage IV staging
- ✓ Directly targets intracranial disease stability
- ✓ Center in Boston medical area
Subsequent-Line Bispecific Antibody vs Chemotherapy in Pretreated Non-Small Cell Lung Cancer
Phase 3 randomized multicenter trial comparing dual-specific immunotherapy versus standard pemetrexed chemotherapy in pretreated metastatic lung adenocarcinoma.
- ✓ Eligible for second-line systemic therapy
- ✓ Acceptable organ metrics and performance status